Navigation Links
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Date:7/20/2009

a sugar pill included dizziness, flu-like symptoms, diarrhea, cough, and tiredness. Other less common reactions to TEKTURNA and TEKTURNA HCT include skin rash and, additionally with TEKTURNA, cough.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "may," "will," "risk," "estimated," "committed," "potential," or similar expressions, or by express or implied discussions regarding potential future indications or labeling for Tekturna or Tekturna HCT, or regarding potential future revenues from Tekturna or Tekturna HCT. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Tekturna or Tekturna HCT will be approved for any additional indications or labeling. Nor can there be any guarantee that Tekturna or Tekturna HCT will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Tekturna and Tekturna HCT could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; unexpected regulatory actions or delays or government regulation generally; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Texas , Nov. 26, 2014 ... today announced the completion of previously announced concurrent ... million.  After fees and estimated offering expenses, Lexicon ... the transactions.  The transactions consisted of: ... common stock, pursuant to a registration statement that ...
(Date:11/26/2014)...  Over 100 million adults suffer from chronic pain ... daily. Chronic and acute pain dramatically impacts quality of ... fulfill the need for non-surgical, interventional solutions and medication ... On October 28th, a new pain management center opened ... community.  This new facility boasts cutting edge technologies ...
(Date:11/26/2014)... 2014  BioScrip ® , Inc. (NASDAQ: BIOS ) ... Executive Officer, will present at the Bank of America Merrill Lynch ... , Date: , , , Wednesday, December 3, 2014 , ... , , , Location: , , , Boca Raton Resort ... Inc. BioScrip, Inc. is a leading national ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3New Pain Management Center Opens in Cumberland, Md. 2
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... there are many medical precautions and procedures in place ... the handling and disposal of things tainted with menstrual ... me to design a simpler, more sanitary way to ... environment," said an inventor from Sonora, Calif. , He ...
(Date:11/27/2014)... Randy Dotinga HealthDay ... Some people,s brains seem pre-wired to acquire a second language, ... their mother tongue will likely gain a brain boost, the ... and integrated after learning," said study co-author Ping Li, co-director ... State University. But it,s even more interesting, Li said, that ...
(Date:11/27/2014)... In order to enable people to adapt to the germaphobic ... to avoid touching a toilet seat and/or lid while raising ... the patent-pending Toilet Tamer, a device that enables a user ... a more sanitary manner. It avoids direct contact with dirty ... good hygiene and peace of mind. The portable device is ...
(Date:11/27/2014)... New York, New York (PRWEB) November 27, 2014 ... behalf of individuals who were allegedly injured by the ... court, where a federal litigation is looking ahead to ... , According to a Scheduling Order issued earlier ... take place on December 16th at 10:00 a.m. Items ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2
... News) -- High blood pressure is associated with a steeper ... study finds. Major decreases in walking speed can affect ... problems; it may also predict who will develop dementia or ... of 643 seniors over 14 years. The participants, who were ...
... organized follow-up care for depression effectively and efficiently, according ... patients that the Journal of General Internal Medicine ... five months, compared to the half of the patients ... had three online care management contacts with a trained ...
... University of Rochester physicians and scientists that has helped ... now more widely available, thanks to approval by the ... the Rochester Nomogram, marks a leap forward for patients ... Refractive surgeon Scott MacRae, M.D., helped develop the formula ...
... Young adults are more likely to be heavy drinkers if they ... also had to cope with stressful life events, a new study ... women and 140 men in Germany who were asked about when ... the previous three years, what daily hassles they might have had ...
... Decisions about whether and how to diagnose children with ... treat them, are sometimes not clear-cut. When decisions lie ... value commitments can reach different but equally respectable conclusions. ... a special report. However, one of the report,s ...
... HealthDay Reporter , TUESDAY, March 15 (HealthDay News) -- ... cell phones while crossing the street, because new research ... than for college students. In laboratory simulations at ... to 81 and 18 undergraduates aged 18 to 26 ...
Cached Medicine News:Health News:High Blood Pressure Linked to Drop in Walking Speed, Study Finds 2Health News:Online messaging delivers follow-up care for depression 2Health News:Rochester technology to enhance eyesight approved by FDA 2Health News:Rochester technology to enhance eyesight approved by FDA 3Health News:Drinking Behavior May Be Tied to Early Alcohol Use 2Health News:Depolarizing the debates about pediatric mental health diagnosis and treatment 2Health News:Depolarizing the debates about pediatric mental health diagnosis and treatment 3Health News:Depolarizing the debates about pediatric mental health diagnosis and treatment 4Health News:Crossing Street While on Cell Phone Risky for Seniors 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: